Denali Therapeutics (DNLI) director receives new RSU and stock option grants

Rhea-AI Filing Summary

Denali Therapeutics director Timothy Van Hauwermeiren received new equity awards as part of his compensation. He was granted 6,408 shares of common stock in the form of Restricted Stock Units (RSUs), each representing a contingent right to one share of Denali common stock.

All of these RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual meeting of stockholders. After this grant, he holds 17,040 RSUs in total, which are all unvested. He was also granted options to purchase 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring in 2036.

Insights

Equity compensation analyst

Routine director compensation via RSU and option grants, not a market trade.

Denali Therapeutics granted director Timothy Van Hauwermeiren 6,408 RSUs and options on 19,226 shares at an exercise price of $19.66. Both awards vest fully after roughly one year or just before the next annual meeting.

These are compensation-related grants under code A, not open-market buying or selling. Following the transaction, he holds 17,040 unvested RSUs and a new option position expiring in 2036. The filing reflects standard board equity incentives rather than a change in personal trading stance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Van Hauwermeiren Timothy

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,226	$0.00	--
Grant/Award	Common Stock	6,408	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 19,226 shares (Direct, null); Common Stock — 17,040 shares (Direct, null)

Footnotes (1)

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Includes 17,040 unvested RSUs. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Key Figures

RSUs granted: 6,408 shares RSUs outstanding: 17,040 shares Options granted: 19,226 shares +2 more

5 metrics

RSUs granted 6,408 shares Common Stock RSU award on June 3, 2026

RSUs outstanding 17,040 shares Unvested RSUs held after grant

Options granted 19,226 shares Stock Option (right to buy) on June 3, 2026

Option exercise price $19.66 per share Strike price for new stock options

Option expiration June 3, 2036 Expiration date of granted stock options

Key Terms

Restricted Stock Unit ("RSU"), contingent right, Stock Option (right to buy), vest, +1 more

5 terms

Restricted Stock Unit ("RSU") financial

"Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right..."

contingent right financial

"and a contingent right to receive one share of common stock of the Issuer."

Stock Option (right to buy) financial

"Stock Option (right to buy)"

vest financial

"100% of the RSUs shall vest upon the earlier of (i) the one year anniversary..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Hauwermeiren Timothy

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		6,408(1)	A	$0	17,040(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.66	06/03/2026		A		19,226		(3)	06/03/2036	Common Stock	19,226	$0	19,226	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

2. Includes 17,040 unvested RSUs.

3. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Denali Therapeutics (DNLI) director Timothy Van Hauwermeiren receive in this Form 4 filing?

He received equity compensation, not a cash transaction. The awards include 6,408 Restricted Stock Units tied to Denali common shares and stock options on 19,226 shares, granted at an exercise price of $19.66 per share.

How many Denali Therapeutics (DNLI) RSUs does Timothy Van Hauwermeiren hold after this grant?

After the grant, he holds 17,040 RSUs in total. A footnote states this amount consists of unvested RSUs, meaning all of these shares are still subject to future vesting conditions before becoming fully owned.

What are the vesting terms for Timothy Van Hauwermeiren’s new RSUs at Denali Therapeutics (DNLI)?

The RSUs vest 100% on a single date. Vesting occurs on the earlier of the one-year anniversary of the grant or the day before Denali’s next annual meeting of stockholders following the grant date, whichever comes first.

What are the key terms of the stock options granted to Timothy Van Hauwermeiren by Denali Therapeutics (DNLI)?

He was granted options on 19,226 shares of common stock with a $19.66 exercise price. These options vest 100% on the same schedule as the RSUs and are scheduled to expire on June 3, 2036, if not exercised earlier.

Does this Denali Therapeutics (DNLI) Form 4 show insider buying or selling in the open market?

No, it shows compensation awards rather than market trades. Both the RSUs and stock options are coded as grants (transaction code A), meaning they were issued by Denali as part of director compensation, without an open-market purchase or sale.

How significant are these equity awards for Timothy Van Hauwermeiren’s Denali Therapeutics (DNLI) holdings?

The filing shows 17,040 RSUs and 19,226 option shares tied to Denali stock. This increases his potential equity exposure but does not involve cash transactions; the ultimate value depends on future stock price and vesting of these awards.